3-<(E)-1-octenyl>cyclopentanone | 64955-00-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-<(E)-1-octenyl>cyclopentanone
• 英文别名: (+/-)-3-(E-1'-Octenyl)-cyclopentanone；(E)-3-(1-octen-1-yl)cyclopentanone；3-(1-octen-1-yl)cyclopentanone；3-((E)-1-Octenyl)-cyclopentanon；3-[(E)-oct-1-enyl]cyclopentan-1-one
• CAS: 64955-00-6
• 化学式: C₁₃H₂₂O
• 分子量: 194.317
• InChiKey: STUILJVWLWQOKX-BQYQJAHWSA-N

物化性质

• 沸点：
  282.4±19.0 °C(Predicted)
• 密度：
  0.954±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-环戊烯酮 、 反式-1-碘-1-辛烯 生成 3-<(E)-1-octenyl>cyclopentanone
  参考文献：
  名称：

  Hydroxylation of prostanoids by fungi. Synthesis of (−)-15-deoxy-19-(R)-hydroxy-PGE₁ and (−)-15-deoxy-18-(S)-hydroxy-PGE₁

  摘要：

  一系列的消旋取代环戊酮已经合成，其中烷基基团对应于上前列腺素侧链和（或）下前列腺素侧链，没有C-15醇基。利用类固醇模板作为前列腺素分子的选择基础，能够羟化类固醇的真菌被用来生物转化前列腺素底物。主要产物在前列腺素C-18和C-19位置发生了羟基化。羟基化是对映选择性的，过量在10-60%范围内，大多数情况下，主要构型与天然前列腺素相对应。发现C-19羟基的立体化学为R，通过将产物降解为甲基6-乙酰氧基庚酸酯，并将该物质与通过结晶乙酸乙酯6-邻苯二甲酰氧基庚酸盐的可分离样品进行比较。C-18的羟基化给出了S构型的醇。观察到前列腺素C-15的羟基化，但在所有情况下，这都伴随着其他反应。利用根霉菌的羟基化制备了（-）-15-去氧-19-(R)-羟基-PGE1和（-）-15-去氧-18-(S)-羟基-PGE1。关键词：生物转化、羟基化、前列腺素、前列腺素。

  DOI：

  10.1139/v90-039

文献信息

• Organo[2-(hydroxymethyl)phenyl]dimethylsilanes as Mild and Reproducible Agents for Rhodium-Catalyzed 1,4-Addition Reactions
  作者：Yoshiaki Nakao、Jinshui Chen、Hidekazu Imanaka、Tamejiro Hiyama、Yoshitaka Ichikawa、Wei-Liang Duan、Ryo Shintani、Tamio Hayashi

  DOI：10.1021/ja071969r

  日期：2007.7.1

  achievement of the corresponding enantioselective transformations using the tetraorganosilicon reagents, providing the silicon-based approach to optically active ketones and substituted piperidones that serve as synthetic intermediates of pharmaceuticals. A rhodium alkoxide species is suggested to be responsible for a transmetalation step on the basis of the observed kinetic resolution of a racemic chiral phenylsilane

  稳定且可重复使用的四有机硅试剂、烯基-、芳基-和甲硅烷基[2-(羟甲基)苯基]二甲基硅烷，在温和的铑催化下与 α,β-不饱和羰基受体发生 1,4-加成反应。该反应耐受多种官能团，适用于克级合成。手性二烯配体的使用允许使用四有机硅试剂实现相应的对映选择性转化，为用作药物合成中间体的光学活性酮和取代哌啶酮提供基于硅的方法。根据观察到的对映选择性 1 中的外消旋手性苯基硅烷的动力学分辨率，建议铑醇盐物种负责金属转移步骤，
• Nickel Acetylacetonate-Induced 1,4-Additions of 1-Alkenyl(Disiamyl)Boranes to α,β-Unsaturated Ketones, Esters and Nitriles
  作者：Teiji Yanagi、Hirotomo Sasaki、Akira Suzuki、Norio Miyaura

  DOI：10.1080/00397919608004563

  日期：1996.7

  conjugate addition of 1-alkenyl(disiamyl)boranes to α,β-unsaturated ketones, esters, or nitriles was carried out in the presence of Ni(acac)2 and triethylamine in DMF. The reactions provided γ,δ-unsaturated ketones, esters, and nitriles in high yields while retaining the original configuration of the 1-alkenylboranes. A similar addition reaction of 1-alkenyl(disiamyl)boranes to 1-acetyl-2-vinylcyclopropane

  摘要 在 Ni(acac)2 和三乙胺的 DMF 存在下，进行了 1-烯基（二异戊基）硼烷与 α,β-不饱和酮、酯或腈的共轭加成。该反应以高产率提供了 γ,δ-不饱和酮、酯和腈，同时保留了 1-烯基硼烷的原始构型。1-烯基（二异戊基）硼烷与 1-乙酰基-2-乙烯基环丙烷的类似加成反应产生末端和内部偶联产物，5,8-链二烯-2-on和5-乙烯基-6-链烯-2-on，在某些情况下以高产率具有有利于末端加成产物的高区域选择性。
• NOVEL PROSTAGLANDIN E1 DERIVATIVE, AND NANOPARTICLE HAVING SAME ENCAPSULATED THEREIN
  申请人：LTT Bio-Pharma Co., Ltd.

  公开号：EP2361918A1

  公开（公告）日：2011-08-31

  A PGE1 derivative is provided which has an excellent sustained, slow-release PGE1 action. In addition, a PGE1-derivative-containing nanoparticle produced using this PGE1 derivative is provided, which effectively targets an affected site, has excellent drug slow-release properties, and has reduced side effects. This PGE1-derivative-containing nanoparticle is a nanoparticle containing a prostaglandin E1 derivative represented by the following formula (1) (wherein n denotes an integer of 1 to 12), obtained by hydrophobicizing the prostaglandin E1 derivative with a metal ion, and reacting tne hydrophobicized prostaglandin E1 derivative with poly L-lactic acid or a poly(L-lactic acid/glycolic acid) copolymer and a poly DL- or L-lactic acid-polyethylene glycol block copolymer or a poly(DL- or L-lactic acid/glycolic acid)-polyethylene glycol block copolymer.

  提供了一种PGE1衍生物，具有出色的持续缓释PGE1作用。此外，提供了一种含有该PGE1衍生物的纳米颗粒，它能有效地靶向受影响的部位，具有优异的药物缓释性能，并减少了副作用。该PGE1衍生物含有纳米颗粒，该纳米颗粒含有以下公式（1）所代表的前列腺素E1衍生物（其中n表示1到12的整数），通过用金属离子使前列腺素E1衍生物疏水化，并将疏水化的前列腺素E1衍生物与聚L-乳酸或聚（L-乳酸/聚乙二醇酸）共聚物和聚DL-或L-乳酸-聚乙二醇嵌段共聚物或聚（DL-或L-乳酸/乙二醇酸）-聚乙二醇嵌段共聚物反应而得到。
• Resolvins: biotemplates for novel therapeutic interventions
  申请人：——

  公开号：US20040116408A1

  公开（公告）日：2004-06-17

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

  本发明一般涉及新型分离治疗剂，称为 "溶解"，由膳食中的ω-3 多不饱和脂肪酸（PUFA）（如二十碳五烯酸（EPA）或二十二碳六烯酸（DHA））、环氧化酶-II（COX-2）和镇痛剂（如阿司匹林（ASA））之间的相互作用产生。令人惊奇的是，在适当的环境中仔细分离由各种成分组合产生的化合物，可以得到具有独特结构和生理特性的二羟基和三羟基 EPA 或 DHA 化合物。因此，本发明提供了许多新的有用的 EPA 或 DHA 的二羟基或三羟基治疗性衍生物（resolvins），这些衍生物可减轻、预防或消除炎症或 PMN 迁移等。本发明还提供了整个说明书中公开的化合物的使用方法、制备方法和用作药物的包装药品。
• Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
  申请人：Serhan N. Charles

  公开号：US20050261255A1

  公开（公告）日：2005-11-24

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

  本发明一般涉及新型分离治疗剂，称为 resolvins，由膳食中的ω-3 多不饱和脂肪酸（PUFA）如二十碳五烯酸（EPA）或二十二碳六烯酸（DHA）、环氧化酶-II（COX-2）和镇痛剂如阿司匹林（ASA）之间的相互作用产生。令人惊奇的是，在适当的环境中仔细分离由各种成分组合产生的化合物，可以得到具有独特结构和生理特性的二羟基和三羟基 EPA 或 DHA 化合物。因此，本发明提供了许多新的有用的 EPA 或 DHA 的二羟基或三羟基治疗性衍生物（resolvins），这些衍生物可减轻、预防或消除炎症或 PMN 迁移等。本发明还提供了整个说明书中公开的化合物的使用方法、制备方法和用作药物的包装药品。